In this article

本文中

LLY

礼来公司

Follow your favorite stocks

关注你喜爱的股票

CREATE FREE ACCOUNT

创建免费账户

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.

2024年3月28日，纽约布鲁克林区摆放的一支礼来公司Zepbound注射笔。

Shelby Knowles | Bloomberg | Getty Images

Shelby Knowles | 彭博社 | 盖蒂图片社

Eli Lilly

礼来公司

on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen.

周一推出了一种新的重磅减肥药 Zepbound，这种药物通过一支笔提供一个月的剂量。

Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level.

现金支付的患者可以在公司的直接面向消费者的网站 LillyDirect 上购买名为 KwikPen 的多剂量装置。最低剂量水平的价格从每月 299 美元起。

The pen could serve as a more convenient option for some patients, as it reduces the number of devices they have to use in a month to take the drug. Patients can use one pen to take four weekly doses of Zepbound.

这种笔可以为一些患者提供更方便的选择，因为它减少了患者一个月内使用药物时需要使用的设备数量。患者可以使用一支笔来服用四次每周剂量的Zepbound。

Currently, patients on the treatment use a different single-dose autoinjector device each week. Lilly also offers single-dose vials of Zepbound, which requires users to draw the medication into a syringe and inject themselves.

目前，接受治疗的患者每周使用不同的单剂量自动注射器装置。礼来公司还提供 Zepbound 的单剂量小瓶，这需要用户将药物抽入注射器并自行注射。

The announcement comes as Lilly works to sustain the early success of Zepbound, which has exploded in demand since it first entered the market in late 2023. LillyDirect has been key to Zepbound's growth, and rolling out a new form of the drug on the platform could attract even more patients.

该公告发布之际，礼来公司正努力维持 Zepbound 的早期成功，自2023年底首次进入市场以来，Zepbound的需求激增。LillyDirect 对 Zepbound 的增长起到了关键作用，在该平台上推出新剂型可能会吸引更多的患者。

The torrid growth of Zepbound has helped Eli Lilly seize a majority share of the weight-loss drug market from rival Novo Nordisk. In the company's fourth quarter, Zepbound brought in $4.2 billion in U.S. revenue, a 122% spike from the previous year.

Zepbound 的迅猛增长帮助礼来公司从竞争对手诺和诺德手中夺取了减肥药市场的大部分份额。在该公司第四季度，Zepbound 在美国创造了 42 亿美元的收入，比前一年增长了 122%。

In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device.

在一份新闻稿中，礼来公司表示，食品药品监督管理局批准了 Zepbound 的标签扩展，以包括多剂量装置。

The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro.

KwikPen 已经用于其他药物，比如礼来公司广受欢迎的糖尿病药物 Mounjaro。

'As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines,' said Ilya Yuffa, the president of Lilly USA and Global Customer Capabilities, in the release. .

“作为我们致力于支持肥胖患者进行体重管理的一部分，我们推出了Zepbound KwikPen这一新选择，这款设备在全球范围内以及美国已被患者广泛信赖用于其他礼来药物，”礼来美国及全球客户能力部门总裁伊利亚·尤法在发布会上表示。